Hydroxyprogesterone caproate

Hydroxyprogesterone caproate
Clinical data
Trade namesDelalutin, Proluton, Proluton Depot, Makena, others
Other namesOHPC; Hydroxyprogesterone capronate; Hydroxyprogesterone hexanoate; 17α-Hydroxyprogesterone caproate; 17α-OHPC; 17-Hydroxyprogesterone caproate; 17-OHPC; 17-HPC; 17α-HPC; HPC; LPCN-1107; 17α-Hydroxypregn-4-ene-3,20-dione 17α-hexanoate
Routes of
administration		• Intramuscular injection[1]
• Subcutaneous autoinjection[2][3]
Drug classProgestogen; Progestin; Progestogen ester; Antigonadotropin
ATC code
Pharmacokinetic data
BioavailabilityOral: Very low (~3% in rats)[4]
Intramuscular: 100% (in rats)[4]
Protein bindingExtensive (to albumin, not to CBG or (likely) SHBG)[1][5][6]
MetabolismReduction and hydroxylation (via CYP3A4, CYP3A5, CYP3A7) and conjugation (glucuronidation, sulfation, acetylation)[1]
Elimination half-lifeNon-pregnant: 7.8 days[7][8]
Singlet: 16–17 days[1][9]
Twins: 10 days[9]
ExcretionFeces: 50%[1]
Urine: 30%[1]
Identifiers
IUPAC name
  • [(8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.010.127
Edit this at Wikidata
Chemical and physical data
FormulaC27H40O4
Molar mass428.613 g·mol−1
3D model (JSmol)
SMILES
  • O=C4\C=C2/[C@]([C@H]1CC[C@@]3([C@@](OC(=O)CCCCC)(C(=O)C)CC[C@H]3[C@@H]1CC2)C)(C)CC4
InChI
  • InChI=1S/C27H40O4/c1-5-6-7-8-24(30)31-27(18(2)28)16-13-23-21-10-9-19-17-20(29)11-14-25(19,3)22(21)12-15-26(23,27)4/h17,21-23H,5-16H2,1-4H3/t21-,22+,23+,25+,26+,27+/m1/s1 checkY
  • Key:DOMWKUIIPQCAJU-LJHIYBGHSA-N checkY
  (verify)

Hydroxyprogesterone caproate (OHPC), sold under the brand names Proluton and Makena among others, is a progestin medication which is used to prevent preterm birth in pregnant women with a history of the condition and to treat gynecological disorders.[1][8][9][10][3] It has also been formulated in combination with estrogens for various indications (brand names Gravibinon and Primosiston) and as a form of long-lasting injectable birth control (brand name Chinese Injectable No. 1).[11] It is not used by mouth and is instead given by injection into muscle or fat, typically once per week to once per month depending on the indication.[1][4][3]

OHPC is generally well tolerated and produces few side effects.[1] Injection site reactions such as pain and swelling are the most common side effect of OHPC.[1] The medication may increase the risk of gestational diabetes when used in pregnant women.[1][12] OHPC is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone.[12] It has some antimineralocorticoid activity and no other important hormonal activity.[13][14][15][16][17] The medication shows a number of differences from natural progesterone.[12][18]

OHPC was discovered in 1953 and was introduced for medical use in 1954 or 1955.[19] It was marketed in the United States under the brand name Delalutin and throughout Europe under the brand name Proluton.[20] The medication was discontinued in the United States in 1999.[21] However, OHPC was subsequently reintroduced in the United States under the brand name Makena for the treatment of preterm birth in 2011.[22] Due to a greatly increased price, a pricing controversy occurred in this country.[22] OHPC was previously available at low cost from compounding pharmacies in the United States, but this became prohibited in 2016.[22][23][24][25]

Medical uses

Preterm birth

The use of OHPC in pregnancy to prevent preterm birth in women with a history of preterm delivery between 20 weeks and 36 weeks and 6 days is supported by the Society of Maternal Fetal Medicine Clinic Guidelines put out in May 2012 as Level I and III evidence, Level A recommendation.[26] Level I evidence refers to a properly powered randomized controlled trial, and level III evidence is support from expert opinion, while a Level A recommendation confers that the recommendation is made based on good and consistent scientific evidence. OHPC 250 mg IM weekly preferably starting at 16–20 weeks until 36 weeks is recommended. In these women, if the transvaginal ultrasound cervical length shortens to <25 mm at < 24 weeks, cervical cerclage may be offered. In the 2013 study the guideline recommendation is based on,[27] there was also a significant decrease of neonatal morbidity including lower rates of necrotizing enterocolitis (0 in the treatment group vs 4 in the control), intraventricular hemorrhage (4 in the treatment group compared with 8 in the control for a relative risk of 0.25), and need for supplemental oxygen (14% in the treatment group vs 24% in the placebo for a relative risk of 0.42). Furthermore, this study contained 463 women, 310 of whom received injection. Of these women, 9 had infants with congenital malformations (2%), but there was no consistent pattern and none involved internal organs.

OHPC is currently (as of June 2014) pregnancy category B, meaning there is no evidence of fetal risk with use of this medication during pregnancy. Although this is now the recommendation, this has not always been the case. A review by Marc Keirse of Flinders University concluded that information about the potential harms was lacking.[28] Three clinical studies in singleton pregnancies of 250 mg/week of intramuscular OHPC have all shown a trend for an increase in pregnancy loss due to miscarriage compared to placebo.[29][30][27] One of them, a large National Institutes of Health (NIH) study in 2003, looked at the effect of OHPC injections in women at risk for repeat premature birth and found that the treated group experienced premature birth in 37% versus 55% in the controls.[27] A follow-up study of the offspring showed no evidence that OHPC affected the children in the first years of life.[31] Based on these NIH data, OHPC was approved by the Food and Drug Administration (FDA) in 2011 as a medication to reduce the risk of premature birth in selected women at risk. (v.i.)

The FDA expressed concern about miscarriage at the 2006 advisory committee meeting; the committee voted unanimously that further study was needed to evaluate the potential association of OHPC with increased risk of second trimester miscarriage and stillbirth.[32] A toxicology study in rhesus monkeys resulted in the death of all rhesus fetuses exposed to 1 and 10 times the human dose equivalent of OHPC.[33] As of 2008, OHPC was a category D progestin according to the FDA (that is, there is evidence of fetal harm). There is speculation that the castor oil in the OHPC formulation may not be beneficial for pregnancy.[34][35] Of note, the above-mentioned NEJM study by Meirs et al. compares the effect of OHPC (with the castor oil component) to castor oil injection as the placebo.

A study published in February 2016 in The Lancet stated the below, amongst other findings:[36]

OPPTIMUM strongly suggests that the efficacy of progesterone in improving outcomes is either non-existent or weak. Given the heterogeneity of the preterm labour syndrome we cannot exclude benefit in specific phenotypic or genotypic subgroups of women at risk. However, the subgroups of women who might benefit do not appear to be easily identifiable by current selection strategies, including cervical length measurement and fibronectin testing. Reassuringly, our study suggests that progesterone is safe for those who wish to take it for preterm birth prophylaxis. The overall rate of maternal or child adverse events was similar in the progesterone and placebo groups. There were few differences in the incidence of adverse secondary outcomes in the two groups, with the exception of a higher rate of renal, gastrointestinal, and respiratory complications in childhood in the progesterone groups. Importantly, the absolute rates of these complications was low. Follow-up of other babies exposed in utero to vaginal progesterone would be helpful in determining whether the increased rate of some renal, gastrointestinal, and respiratory complications is a real effect or a type I error.

The journal reviewer Richard Lehman, senior Research Fellow at the Department of Primary Health Care at the University of Oxford, made the following notable commentary on the OPPTIMUM study: "That's it. This story is ended, and nobody need ever use vaginal progesterone again to prevent preterm birth."[37]

A Cochrane review on progestogen for preventing preterm birth concluded that there was little evidence that either vaginal or intramuscular progesterone helped to reduce the risk of preterm birth in women with a multiple pregnancy.[38]

Gynecological disorders

OHPC is used in the treatment of threatened miscarriage, gynecological disorders such as dysmenorrhea, premenstrual syndrome, fibrocystic breast disease, adenosis, and breast pain.[9] In addition, OHPC is used in the treatment of endometrial cancer and has been found to be significantly effective in extending life in both premenopausal and postmenopausal women with the disease.[39] The medication was used widely in the 1950s through the 1970s for such indications, but OHPC more recently has received the most attention in the prevention of preterm birth.[9]

Birth control

OHPC is available in combination with estradiol valerate as a once-monthly combined injectable contraceptive in a few countries.[11][40]

Other uses

OHPC has been used as a component of menopausal hormone therapy in women.[41][42]

OHPC has been used to treat benign prostatic hyperplasia in men, although evidence of effectiveness is marginal and uncertain.[43] It has also been used to treat prostate cancer, at a dosage of 1,500 mg twice per week.[44][45][46][47] The mechanism of action of OHPC in these uses is suppression of testicular androgen production via suppression of luteinizing hormone secretion, which are the result of the progestogenic and antigonadotropic activity of OHPC.[43] However, symptoms of hypogonadism may develop when OHPC is used for this indication, with two-thirds of men reportedly experiencing impotence.[48]

OHPC has been used as a component of feminizing hormone therapy for transgender women.[49][50][51][52][53] Due to micronization, bioidentical progestogens are more commonly used.

Available forms

Single-use packs of Proluton Depot (OHPC). Contain 1-mL ampoules of 250 mg/mL hydroxyprogesterone caproate (250 mg total) in castor oil and benzyl benzoate solution as well as a 21 G needles and disposable syringes and indicated for use by intramuscular injection.

OHPC is available alone in the form of ampoules and vials of 125 and 250 mg/mL oil solutions for intramuscular injection (brand names Proluton, Makena).[54][55] It is also available alone in the form of a 250 mg/mL autoinjector for use by subcutaneous injection (brand name Makena).[3]

OHPC is or was available in combination with estradiol valerate in the form of ampoules and vials of 250 mg/mL OHPC and 5 mg/mL estradiol valerate oil solutions for intramuscular injection (brand names Gravibinon, Chinese Injectable No. 1).[56][57][58][59] The medication is or was available in combination with estradiol benzoate in the form of ampoules of 125–250 mg OHPC and 10 mg estradiol benzoate in oil solution for intramuscular injection (brand name Primosiston) as well.[60][61][62][63][64]: 1045  In addition, OHPC has been marketed in combination with estradiol dipropionate in the form of 50 mg/mL OHPC and 1 mg/mL estradiol dipropionate (brand name EP Hormone Depot) in Japan.[65][66]

Contraindications

Contraindications of OHPC include previous or current thrombosis or thromboembolic disease, known or suspected breast cancer, past or present history of other hormone-sensitive cancer, undiagnosed abnormal vaginal bleeding unrelated to pregnancy, cholestatic jaundice of pregnancy, liver tumors or active liver disease, and uncontrolled hypertension.[3] A few relative contraindications also exist for OHPC.[3]

Side effects

OHPC is generally well tolerated and produces relatively few side effects.[1] Injection site reactions such as pain, soreness, swelling, itching, bruising, and lumps are the most common side effect of OHPC.[1] In contrast to large doses of progesterone however, which produce moderate-to-severe such reactions, OHPC is relatively free from injection site reactions.[67] Side effects of OHPC that occur in greater than or equal to 2% of users include injection site pain (34.8%), injection site swelling (17.1%), urticaria (12.3%), pruritus (7.7%), injection site pruritus (5.8%), nausea (5.8%), injection site nodules (4.5%), and diarrhea (2.3%).[3] Numerically increased rates relative to controls of miscarriage (2.4% vs. 0%), stillbirth (2.0% vs. 1.3%), admission for preterm labor (16.0% vs. 13.8%), preeclampsia or gestational hypertension (8.8% vs. 4.6%), gestational diabetes (5.6% vs. 4.6%),[1][12] and oligohydramnios (3.6% vs. 1.3%) have been observed with OHPC in clinical trials in which it was given to pregnant women to prevent preterm birth.[3]

Overdose

There have been no reports of overdose of OHPC.[3] In the event of overdose, treatment should be based on symptoms.[3] OHPC has been studied in humans at high doses of 2,000 to 5,000 mg per week by intramuscular injection, without safety concerns.[7][17][68][69]

Interactions

OHPC is not likely to affect most cytochrome P450 enzymes at therapeutic concentrations.[3] Drug interaction studies have not been performed with OHPC.[3]

Pharmacology

Pharmacodynamics

OHPC has progestogenic activity, some antimineralocorticoid activity, and no other important hormonal activity.[13][8][14][15][68]

Relative affinities (%) of hydroxyprogesterone and related steroids
CompoundhPR-AhPR-BrbPRrbGRrbER
Progesterone100100100<1<1
17α-Hydroxyprogesterone1131<1
Hydroxyprogesterone caproate2630284<1
Hydroxyprogesterone acetate38461153 ?
Notes: Values are percentages (%). Reference ligands (100%) were progesterone for the PR, dexamethasone for the GR, and estradiol for the ER. Sources: See template.
Parenteral potencies and durations of progestogens[lower-alpha 1][lower-alpha 2]
Compound Form Dose for specific uses (mg)[lower-alpha 3] DOA[lower-alpha 4]
TFD[lower-alpha 5] POICD[lower-alpha 6] CICD[lower-alpha 7]
Algestone acetophenideOil soln.-–75–15014–32 d
Gestonorone caproateOil soln.25–50––8–13 d
Hydroxyprogest. acetate[lower-alpha 8]Aq. susp.350––9–16 d
Hydroxyprogest. caproateOil soln.250–500[lower-alpha 9]–250–5005–21 d
Medroxyprog. acetateAq. susp.50–1001502514–50+ d
Megestrol acetateAq. susp.-–25>14 d
Norethisterone enanthateOil soln.100–2002005011–52 d
ProgesteroneOil soln.200[lower-alpha 9]––2–6 d
Aq. soln. ?––1–2 d
Aq. susp.50–200––7–14 d
Notes and sources:
  1. ↑ Sources: [70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85][86][87][88][89]
  2. ↑ All given by intramuscular or subcutaneous injection.
  3. ↑ Progesterone production during the luteal phase is ~25 (15–50) mg/day. The OID of OHPC is 250 to 500 mg/month.
  4. ↑ Duration of action in days.
  5. ↑ Usually given for 14 days.
  6. ↑ Usually dosed every two to three months.
  7. ↑ Usually dosed once monthly.
  8. ↑ Never marketed or approved by this route.
  9. 1 2 In divided doses (2 × 125 or 250 mg for OHPC, 10 × 20 mg for P4).

Progestogenic activity

OHPC, also known as 17α-hydroxyprogesterone caproate, is closer to progesterone in terms of structure and pharmacology than most other progestins, and is essentially a pure progestogen – that is, a selective agonist of the progesterone receptor (PR) with minimal or no other hormonal activity.[16][17] However, OHPC has improved pharmacokinetics compared to progesterone, namely a much longer duration with intramuscular injection in oil solution.[9][90][61][91]

Administered by intramuscular injection, the endometrial transformation dosage of OHPC per cycle is 250 to 500 mg, and the weekly substitution dosage of OHPC is 250 mg, while the effective dosage of OHPC in the menstrual delay test (Greenblatt) is 25 mg per week.[61][91][92] An effective ovulation-inhibiting dosage of OHPC is 500 mg once per month by intramuscular injection.[58][93][94] However, the dose of OHPC used in once-a-month combined injectable contraceptives is 250 mg, and this combination is effective for inhibition of ovulation similarly.[58][94] For comparison, the dose of medroxyprogesterone acetate (MPA; 6α-methyl-17α-hydroxyprogesterone acetate), a close analogue of OHPC, used by intramuscular injection in microcrystalline aqueous suspension in once-a-month combined injectable contraceptives, is 25 mg.[58][93] It has also been said that given by intramuscular injection, 250 mg OHPC in oil solution is equivalent in progestogenic potency to 50 mg medroxyprogesterone acetate in microcrystalline aqueous suspension.[95] Although the elimination half-life of intramuscular OHPC in oil solution in non-pregnant women is about 8 days,[7][8] the elimination half-life of intramuscular medroxyprogesterone acetate in microcrystalline aqueous suspension in women is around 50 days.[96] OHPC is also to some degree less potent than the more closely related ester hydroxyprogesterone acetate (OHPA; 17α-hydroxyprogesterone acetate).[97]

17α-Hydroxyprogesterone (OHP) has weak progestogenic activity, but C17α esterification results in higher progestogenic activity.[64] Of a variety of different esters, the caproate (hexanoate) ester was found to have the strongest progestogenic activity, and this served as the basis for the development of OHPC, as well as other caproate progestogen esters such as gestonorone caproate.[64] OHPC is a much more potent progestogen than 17α-hydroxyprogesterone, but does not have as high of affinity for the PR as progesterone.[97] OHPC has about 26% and 30% of the affinity of progesterone for the human PR-A and PR-B, respectively.[1][97] The medication was no more efficacious than progesterone in activating these receptors and eliciting associated gene expression in vitro.[1][97]

Antigonadotropic effects

Due to activation of the PR, OHPC has antigonadotropic effects, or produces suppression of the hypothalamic–pituitary–gonadal axis,[98][99] and can significantly suppress gonadotropin secretion and gonadal sex hormone production at sufficiently high doses.[47] One study found that OHPC by intramuscular injection at a dosage of 200 mg twice weekly for the first two weeks and then 200 mg once weekly for 12 weeks did not significantly influence urinary excretion of estrogens, luteinizing hormone, or follicle-stimulating hormone in men with benign prostatic hyperplasia.[100] In another study that used an unspecified dosage of intramuscular OHPC, testosterone secretion was assessed in a single man and was found to decrease from 4.2 mg/day to 2.0 mg/day (or by approximately 52%) by 6 weeks of treatment, whereas secretion of luteinizing hormone remained unchanged in the man.[16] Yet another study found that 3,000 mg/week OHPC by intramuscular injection suppressed testosterone levels from 640 ng/dL to 320–370 ng/dL (by 42–50%) in a single man with prostate cancer, which was similar to the testosterone suppression with cyproterone acetate or chlormadinone acetate.[101] Gestonorone caproate, a closely related progestin to OHPC with about 5- to 10-fold greater potency in humans,[102][103] was found to suppress testosterone levels by 75% at a dosage of 400 mg/week in men with prostate cancer.[104][105] For comparison, orchiectomy decreased testosterone levels by 91%.[104] In general, progestins are able to maximally suppress testosterone levels by about 70 to 80%.[106][107][108][104][105] The antigonadotropic effects of OHPC and hence its testosterone suppression are the basis of the use of OHPC in the treatment of benign prostatic hyperplasia and prostate cancer in men.[43][44][46][47] Suppression of luteinizing hormone levels by OHPC has also been observed in women.[109][103]

Glucocorticoid activity

OHPC is said not to have any glucocorticoid activity.[17] In accordance, OHPC has been found not to alter cortisol levels in humans even with very high doses by intramuscular injection.[7] This is of relevance because medications with significant glucocorticoid activity suppress cortisol levels due to increased negative feedback on the hypothalamic–pituitary–adrenal axis.[54][110][111] OHPC has been studied in humans at doses as high as 5,000 mg per week by intramuscular injection, with safety and without glucocorticoid effects observed.[7][69] The medication does interact with the glucocorticoid receptor however; it has about 4% of the affinity of dexamethasone for the rabbit glucocorticoid receptor.[1][97] But it acts as a partial agonist of the receptor and has no greater efficacy than progesterone in activating the receptor and eliciting associated gene expression in vitro.[1][97][112]

Other activities

As a pure progestogen, OHPC has no androgenic, antiandrogenic, estrogenic, or glucocorticoid activity.[16][17][113] The absence of androgenic and antiandrogenic activity with OHPC is in contrast to most other 17α-hydroxyprogesterone-derivative progestins.[90][113] Due to its lack of androgenic properties, similarly to progesterone, OHPC does not have any teratogenic effects on the fetus, making it safe for use during pregnancy.[17] Although OHPC has been described as a pure progestogen, there is evidence that it possesses some antimineralocorticoid activity, similarly to progesterone and 17α-hydroxyprogesterone.[14][114][15] This includes clinically important diuretic effects and reversal of estrogen-induced fluid retention and edema.[114] Unlike progesterone, OHPC and its metabolites are not anticipated to interact with non-genomic receptors such as membrane progesterone receptors or the GABAA receptor.[18] In accordance, OHPC is not thought to possess the neurosteroid activities of progesterone or its associated sedative effects.[18]

In relation to cytochrome P450 enzymes, OHPC has no effect on CYP1A, CYP2D6, CYP2C9, or CYP3A4, but is a modest inducer of CYP2C19.[9]

Differences from progesterone

There are pharmacodynamic differences between progesterone and OHPC, which may have implications for obstetrical use.[12][18] These include:[12][18]

Differences in the metabolism of progesterone and OHPC and differences in the formation and activities of metabolites may be responsible for or involved in these observed biological and pharmacological differences.[18] Progesterone is metabolized by 5α- and 5β-reductases, 3α- and 3β-hydroxysteroid dehydrogenases, and 20α- and 20β-hydroxysteroid dehydrogenase in various tissues.[18][116] In target tissues, particularly the cervix and myometrium, these enzymes regulate local progesterone concentrations and can activate or inactivate progesterone signaling.[18] In addition, these enzymes catalyze the formation of metabolites of progesterone such as 5β-dihydroprogesterone and allopregnanolone, which signal through their own non-genomic receptors such as membrane progesterone receptors and the GABAA receptor and have their own important effects in pregnancy.[115][117][118] As examples, 5β-dihydroprogesterone has been found to play an important role in suppressing myometrial activity while allopregnanolone has potent sedative and anesthetic effects in the mother and especially the fetus and is involved in fetal nervous system development.[18][117][118][119][120] In contrast to progesterone, OHPC is not metabolized by traditional steroid-transforming enzymes and instead is metabolized exclusively via oxidation at the caproate side chain by cytochrome P450 enzymes.[18] As such, it is not thought to have the same tissue-specific activation and inactivation patterns that progesterone does nor the same non-genomic actions that progesterone and its metabolites possess.[18]

Further clinical research is anticipated to provide additional data to help clarify the issue of safety with OHPC.[12] In any case, it has been recommended by the American College of Obstetricians and Gynecologists that pregnant women treated with OHPC receive counseling about its risks and benefits.[12]

Pharmacokinetics

Pharmacokinetics of OHPCa in pregnant women
ParameterSingletonTwin
Cmax (ng/mL)22.6 (15.8–27.4)17.3 (12–27)
Cmean(0–t) (ng/mL)16.8 (12.8–22.7)12.3 (8.4–18.7)
Ctrough (ng/mL)14.1 (10–18.1)11.2 (4.8–16.3)
AUC0–t (ng/mL/day)117.3 (89.9–159.1)86.1 (59–131)
t1/2 (days)16.2 (10.6–21.0)10 (6–16)
Tmax (days)1.0 (1–3)1.2 (1–2)
Vd/F (×103) (L)56 (25.2–69.6)16.9 (9.1–24.5)
Cl/F (×103) (L)2.1 (1.5–2.7)1.2 (0.9–1.7)
Footnotes: a = OHPC 250 mg once per week by intramuscular injection. Sources: [9][121][122]

Absorption

In animals, the bioavailability of OHPC with intramuscular injection is nearly 100%, but its oral bioavailability is very low at less than 3%.[4] In women, 70 mg/day oral OHPC has similar endometrial potency as 70 mg/day oral OHPA and 2.5 mg/day oral medroxyprogesterone acetate, indicating that oral OHPC and OHPA have almost 30-fold lower potency than medroxyprogesterone acetate via oral administration.[123] Studies on progestogenic endometrial changes with oral OHPC in women are mixed however, with one finding weak effects with 100 mg/day whereas another found that doses of 250 to 1,000 mg produced no effects.[124][125] As a result of its low oral potency, OHPC has not been used by the oral route and has instead been administered by intramuscular injection.[4] However, a novel oral formulation of OHPC (developmental code name LPCN-1107) is under development and has been found to be effective, though it required administration twice a day in a clinical study.[126][127][128]

A depot effect occurs when OHPC is injected intramuscularly or subcutaneously, such that the medication has a prolonged duration of action.[2][9] Following a single intramuscular injection of 1,000 mg OHPC in five women with endometrial cancer, peak levels of OHPC were 27.8 ± 5.3 ng/mL and the time to peak concentrations was 4.6 ± 1.7 (3–7) days.[7][129] Following 13 weeks of continuous administration of 1,000 mg OHPC per week, trough levels of OHPC were 60.0 ± 14 ng/mL.[7][129] The pharmacokinetic parameters of 250 mg OHPC once per week by intramuscular injection have also been studied in pregnant women with singleton and multiple (twin and triplet) gestation.[9][121][122] Steady state levels of the medication are achieved within 4 to 12 weeks of administration in pregnant women.[1] The duration of clinical biological effect of OHPC by intramuscular injection has also been studied in women.[130] A single intramuscular injection of 65 to 500 mg OHPC in oil solution has been found to have a duration of action of 5 to 21 days in terms of effect in the uterus and on body temperature in women.[130]

OHPC has been found to possess similar pharmacokinetics, including peak levels, time to peak levels, area-under-the-curve levels (i.e., total exposure), and elimination half-life, with administration via intramuscular injection or subcutaneous autoinjection.[2] However, there was a higher incidence of injection site pain with subcutaneous autoinjection than with intramuscular injection (37.3% vs. 8.2%).[2]

Distribution

OHPC is extensively bound to plasma proteins, of which include albumin.[1] Unlike progesterone and 17α-hydroxyprogesterone, OHPC has very low affinity for corticosteroid-binding globulin (less than 0.01% of that of cortisol).[5] Progesterone and 17α-hydroxyprogesterone have low affinity for sex hormone-binding globulin, and for this reason, only a very small fraction of them (less than 0.5%) is bound to this protein in the circulation.[6]

Metabolism

OHPC appears to be metabolized primarily by the cytochrome P450 enzymes CYP3A4 and CYP3A5.[1] It may also be metabolized by CYP3A7 in fetal liver and the placenta.[1] Unlike progesterone, OHPC is not metabolized by traditional steroid-transforming enzymes and does not form similar metabolites.[18] The metabolism of OHPC is by reduction, hydroxylation, and conjugation, including glucuronidation, sulfation, and acetylation.[18] The caproate ester of OHPC is not cleaved during metabolism, so 17α-hydroxyprogesterone is not formed from OHPC.[18][97] As such, OHPC is not a prodrug of 17α-hydroxyprogesterone, nor of progesterone.[18][97]

OHPC has been found to have an elimination half-life of 7.8 days when given by intramuscular injection in an oil-based formulation to non-pregnant women.[7][8] Its total duration is said to be 10 to 14 days, which is much longer than the duration of intramuscularly administered progesterone in an oil formulation (2 to 3 days).[131] In pregnant women, the elimination half-life of OHPC appears to be longer, about 16 or 17 days.[1][9] However, in women pregnant with twins rather than a singlet, the elimination half-life of OHPC was found to be shorter than this, at 10 days.[9] OHPC has been detected in pregnant women up to 44 days after the last dose.[9]

Elimination

OHPC is eliminated 50% in feces and 30% in urine when given by intramuscular injection to pregnant women.[1] Both the free steroid and conjugates are excreted by these routes, with the conjugates more prominent in feces.[1]

Veterinary

The pharmacokinetics of OHPC in various ungulates including cattle, buffalo, sheep, and goat have been studied.[132]

Time–concentration curves

Chemistry

OHPC, also known as 17α-hydroxyprogesterone caproate or as 17α-hydroxypregn-4-ene-3,20-dione 17α-hexanoate, is a synthetic pregnane steroid and a derivative of progesterone.[20][133] It is specifically a derivative of 17α-hydroxyprogesterone with a hexanoate (caproate) ester at the C17α position.[20][133] Analogues of OHPC include other 17α-hydroxyprogesterone derivatives such as algestone acetophenide (dihydroxyprogesterone acetophenide), chlormadinone acetate, cyproterone acetate, hydroxyprogesterone acetate, hydroxyprogesterone heptanoate, medroxyprogesterone acetate, and megestrol acetate, as well as the caproate esters chlormadinone caproate, gestonorone caproate (norhydroxyprogesterone caproate), medroxyprogesterone caproate, megestrol caproate, and methenmadinone caproate.[20][133]

Synthesis

Chemical syntheses of OHPC have been described.[134][135][136]: 6 

History

Along with hydroxyprogesterone acetate, OHPC was developed by Karl Junkmann of Schering AG in 1953 and was first reported by him in the medical literature in 1954.[137][138][139][140][141] It was reportedly first marketed in Japan in 1954 or 1955,[19] and was subsequently introduced as Delalutin in the United States in 1956.[9][142] Due to its much longer duration than parenteral progesterone, OHPC had largely replaced progesterone in clinical practice by 1975.[143] After decades of use, Squibb, the manufacturer, voluntarily withdrew the Delalutin product in the United States in 1999.[21] Renewed interest in OHPC in the United States was sparked with a large NIH-sponsored study in 2003 that found that OHPC reduced the risk of premature birth in selected at-risk pregnant women.[27] With follow-up data showing no evidence of harmful effects on the offspring, the FDA approved the medication, as sponsored by KV Pharmaceutical as Makena, as an orphan drug in February 2011 to reduce the risk of premature birth in women prior to 37 weeks gestation with a single fetus who had at least one previous premature birth.[22][144]

Society and culture

Generic names

Hydroxyprogesterone caproate is the generic name of OHPC and its INN, USAN, BANM, and JAN, while hydroxyprogesterone hexanoate was its former BANM.[20][40][133]

OHPC is often mislabeled as and confused with progesterone and 17α-hydroxyprogesterone.[145] It should also not be confused with hydroxyprogesterone acetate, hydroxyprogesterone heptanoate, or medroxyprogesterone acetate.[133]

Brand names

OHPC is marketed throughout the world under a variety of brand names including Proluton, Proluton Depot, and Makena (US), among many others.[20][40][133] It was also formerly marketed under brand names including Delalutin, Prodrox, and Hylutin among others, but these formulations have since been discontinued.[20][133] It has been marketed under the brand names Gravibinon and Injectable No. 1 (or Chinese Injectable No. 1) in combination with estradiol valerate[56][57][58][59] and under the brand name Primosiston in combination with estradiol benzoate.[60][61][62][63][64]

Availability

Known availability of OHPC in countries throughout the world (as of August 2018). Alone is OHPC as a standalone medication. With E2 is in combination with an estradiol ester. Discontinued is no longer available.

OHPC is marketed in the United States and throughout Europe, Asia, and Central and South America.[20][40][146] It is notably not available in Canada, the United Kingdom, New Zealand, or South Africa, and only veterinary formulations are available in Australia.[20][40][146] OHPC is also marketed in combination with estradiol valerate as a combined injectable contraceptive in a number of countries including in South America, Mexico, Japan, and China.[20][40][146] It has been marketed as an injectable preparation in combination with estradiol benzoate in some countries as well.[60][61][62][63][64]

Price controversy

With the designation of OHPC as an orphan drug by the FDA and approval of Makena in 2011, the price of OHPC in the United States was going to increase from US$15 to US$1,500 for a single dose, or from about US$300 to between US$25,000 and US$30,000 for a typical single month of treatment.[22] This was about a 100-fold increase in cost, with "minimal added clinical benefit", and was a strongly criticized pricing strategy.[22] The FDA subsequently announced that compounding pharmacies could continue to sell OHPC at their usual cost of approximately US$10 to US$20 per dose without fear of legal reprisals.[22][23] KV Pharmaceutical also opted to reduced its price of Makena to US$690 per dose.[22][147] OHPC continued to be available at low cost from compounding pharmacies until late 2016, after which time the FDA published new guidance documents prohibiting compounding pharmacies from selling products that are "essentially copies" of commercially available drug products.[24][25]

Research

Cyclical therapy with 150 mg OHPC by intramuscular injection was found to be effective in the treatment of 76 women with persistent, treatment-refractory acne in a preliminary study, with 84% responding to the therapy and experiencing a "good-to-excellent" improvement in symptoms.[131][148]

OHPC was studied by Schering for use as a progestogen-only injectable contraceptive at a dose of 250 to 500 mg once a month by intramuscular injection but produced poor cycle control at these doses and was never marketed.[149][150]

OHPC by itself has been found to have little or no effectiveness in the treatment of breast cancer in women.[64][151][152][153] Conversely, the combination of estradiol valerate and OHPC has been found to be effective in the treatment of breast cancer in women.[64][114][154] Initial research based on limited clinical data reported that the breast-cancer response rate with a combination of estradiol valerate and OHPC seemed to be greater than with an estrogen alone (35% vs. 50%).[64] However, subsequent research using the related but more potent progestin gestonorone caproate found that the combination of estradiol valerate and gestonorone caproate had effectiveness that was not significantly different from that of an estrogen alone in the treatment of breast cancer in women.[155]

A novel oral formulation of OHPC (developmental code name LPCN-1107) is under development for the prevention of preterm labor.[126][127] As of September 2017, it is in phase II or phase III clinical trials for this indication.[126]

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Deeks ED (October 2011). "17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth". Paediatric Drugs. 13 (5): 337–45. doi:10.2165/11208140-000000000-00000. PMID 21888448. S2CID 207297651.
  2. 1 2 3 4 Krop J, Kramer WG (December 2017). "Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study". Clinical Therapeutics. 39 (12): 2345–2354. doi:10.1016/j.clinthera.2017.10.020. PMID 29191450.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021945s012lbl.pdf
  4. 1 2 3 4 5 Shaik IH, Bastian JR, Zhao Y, Caritis SN, Venkataramanan R (2015). "Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 46 (2): 169–74. doi:10.3109/00498254.2015.1057547. PMC 4809632. PMID 26153441.
  5. 1 2 Mickelson KE, Forsthoefel J, Westphal U (October 1981). "Steroid-protein interactions. Human corticosteroid binding globulin: some physicochemical properties and binding specificity". Biochemistry. 20 (21): 6211–8. doi:10.1021/bi00524a047. PMID 7306509.
  6. 1 2 Dunn JF, Nisula BC, Rodbard D (July 1981). "Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma". The Journal of Clinical Endocrinology and Metabolism. 53 (1): 58–68. doi:10.1210/jcem-53-1-58. PMID 7195404.
  7. 1 2 3 4 5 6 7 8 9 Onsrud M, Paus E, Haug E, Kjørstad K (1985). "Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function". Acta Obstetricia et Gynecologica Scandinavica. 64 (6): 519–23. doi:10.3109/00016348509156732. PMID 2932883. S2CID 12007439.
  8. 1 2 3 4 5 Hines M, Lyseng-Williamson KA, Deeks ED (March 2013). "17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth". Clinical Drug Investigation. 33 (3): 223–7. doi:10.1007/s40261-013-0060-6. PMID 23413110. S2CID 23221264.
  9. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Feghali M, Venkataramanan R, Caritis S (December 2014). "Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations". Seminars in Perinatology. 38 (8): 516–22. doi:10.1053/j.semperi.2014.08.013. PMC 4253874. PMID 25256193.
  10. ↑ Manuck TA (December 2017). "17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?". Seminars in Perinatology. 41 (8): 461–467. doi:10.1053/j.semperi.2017.08.004. PMID 28947068.
  11. 1 2 Newton JR, D'arcangues C, Hall PE (1994). "A review of "once-a-month" combined injectable contraceptives". Journal of Obstetrics and Gynaecology. 4 Suppl 1: S1-34. doi:10.3109/01443619409027641. PMID 12290848.
  12. 1 2 3 4 5 6 7 8 Romero R, Stanczyk FZ (June 2013). "Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice". American Journal of Obstetrics and Gynecology. 208 (6): 421–6. doi:10.1016/j.ajog.2013.04.027. PMC 4120746. PMID 23643669.
  13. 1 2 Horsky J, Presl J (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 95–. ISBN 978-94-009-8195-9.
  14. 1 2 3 Dorfman RI (5 December 2016). Steroidal Activity in Experimental Animals and Man. Elsevier Science. pp. 398–. ISBN 978-1-4832-7299-3. Intramuscular administration of 17α-hydroxyprogesterone caproate produced signs and symptoms of adrenal insufficiency in Addisonians maintained on cortisol and 9α-fluorocortisol (Melby, 1961) and thereby showed properties similar to progesterone and 17α-hydroxyprogesterone. However, further tests will be required to eludicate its pharmacodynamics properties. Contrastingly, there was no evidence for salt dissipation with the test of a smaller dose of the steroid to normal subjects (Landau et al., 1958).
  15. 1 2 3 Sammour MB, El-Kabarity H, Khalifa AS (1975). "Progesterone therapy in pre-eclamptic toxaemia". Acta Obstetricia et Gynecologica Scandinavica. 54 (3): 195–202. doi:10.3109/00016347509157760. PMID 1163210. S2CID 38002155. Melby (14) found that when progesterone was administered to patients suffering from the syndrome of idiopathic oedema, they experienced a diuresis, with a high excretion of sodium and water within 24 hours after a single injection of 500 mg of 17-α-hydroxyprogesterone caproate.
  16. 1 2 3 4 Geller J, Bora R, Roberts T, Newman H, Lin A, Silva R (July 1965). "Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate: effect on clinical symptoms, morphology, and endocrine function". JAMA. 193 (2): 121–8. doi:10.1001/jama.1965.03090020035009. PMID 14304354.
  17. 1 2 3 4 5 6 Meis PJ (May 2005). "17 hydroxyprogesterone for the prevention of preterm delivery". Obstetrics and Gynecology. 105 (5 Pt 1): 1128–35. doi:10.1097/01.AOG.0000160432.95395.8f. PMID 15863556.
  18. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Byrns MC (January 2014). "Regulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birth". The Journal of Steroid Biochemistry and Molecular Biology. 139: 173–81. doi:10.1016/j.jsbmb.2013.01.015. PMID 23410596. S2CID 23414730.
  19. 1 2 International Agency for Research on Cancer (1979). Sex Hormones (II). International Agency for Research on Cancer. p. 401. ISBN 978-92-832-1221-8. 17α-Hydroxyprogesterone caproate was first marketed commercially in Japan in 1954-1955.
  20. 1 2 3 4 5 6 7 8 9 10 Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 532–. ISBN 978-3-88763-075-1.
  21. 1 2 Kim S. "The Orphan Drug Act: How the FDA Unlawfully Usurped Market Exclusivity". Northwestern Journal of Technology and Intellectual Property. Heinonline. 11: &#91, v&#93.
  22. 1 2 3 4 5 6 7 8 Armstrong J (May 2011). "Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP". The New England Journal of Medicine. 364 (18): 1689–91. doi:10.1056/NEJMp1102796. PMID 21410391.
  23. 1 2 "Macleans.ca - Canada's national current affairs and news magazine since 1905". Archived from the original on 2011-12-14. Retrieved 2011-03-30.
  24. 1 2 Research, Center for Drug Evaluation and (2019-04-01). "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry". U.S. Food and Drug Administration. Retrieved 2019-06-14.
  25. 1 2 "FDA to Restrict Compounders from Making Copies of Commercially Available Drugs". RAPS.com. 2016-07-07. Retrieved 2019-06-14.
  26. ↑ SMFM Clinical Guideline: Progesterone and preterm birth prevention: translating clinical trials data into clinical practice, AJOG May 2012
  27. 1 2 3 4 Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. (June 2003). "Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate". The New England Journal of Medicine. 348 (24): 2379–85. doi:10.1056/NEJMoa035140. PMID 12802023.
  28. ↑ Keirse MJ (September 2004). "Progesterone and preterm: seventy years of "déjà vu" or "still to be seen"?". Birth. 31 (3): 230–5. doi:10.1111/j.0730-7659.2004.00315.x. PMID 15330887.
  29. ↑ Johnson JW, Austin KL, Jones GS, Davis GH, King TM (October 1975). "Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor". The New England Journal of Medicine. 293 (14): 675–80. doi:10.1056/nejm197510022931401. PMID 1099445.
  30. ↑ Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I, Lancet M (March 1985). "Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate". American Journal of Obstetrics and Gynecology. 151 (5): 574–7. doi:10.1016/0002-9378(85)90141-3. PMID 3976757.
  31. ↑ Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, Swain M, Bousleiman S, Johnson F, Dorman K, Milluzzi C, Tillinghast JA, Kerr M, Mallett G, Thom E, Pagliaro S, Anderson GD (October 2007). "Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo". Obstetrics and Gynecology. 110 (4): 865–72. doi:10.1097/01.AOG.0000281348.51499.bc. PMID 17906021. S2CID 29485152.
  32. ↑ Advisory Committees: CDER 2006 Meeting Documents
  33. ↑ Hendrickx AG, Korte R, Leuschner F, Neumann BW, Poggel A, Binkerd P, Prahalada S, Günzel P (February 1987). "Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate". Teratology. 35 (1): 129–36. doi:10.1002/tera.1420350116. PMID 3563931.
  34. ↑ Duke University Medical Center, New England Journal of Medicine, correspondence, vol 349.
  35. ↑ Hauth JC, Gilstrap LC, Brekken AL, Hauth JM (May 1983). "The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population". American Journal of Obstetrics and Gynecology. 146 (2): 187–90. doi:10.1016/0002-9378(83)91051-7. PMID 6682631.
  36. ↑ Norman JE, Marlow N, Messow CM, Shennan A, Bennett PR, Thornton S, Robson SC, McConnachie A, Petrou S, Sebire NJ, Lavender T, Whyte S, Norrie J (May 2016). "Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial". Lancet. 387 (10033): 2106–2116. doi:10.1016/S0140-6736(16)00350-0. PMC 5406617. PMID 26921136.
  37. ↑ "BMJ Blogs: The BMJ » Blog Archive » Richard Lehman's journal review—23 May 2016". blogs.bmj.com. 2016-05-23. Retrieved 2016-05-25.
  38. ↑ Dodd, JM; Grivell, RM; OBrien, CM; Dowswell, T; Deussen, AR (20 November 2019). "Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy". The Cochrane Database of Systematic Reviews. 2019 (11). doi:10.1002/14651858.CD012024.pub3. PMC 6864412. PMID 31745984.
  39. ↑ Reifenstein EC (March 1971). "Hydroxyprogesterone caproate therapy in advanced endometrial cancer". Cancer. 27 (3): 485–502. doi:10.1002/1097-0142(197103)27:3<485::AID-CNCR2820270302>3.0.CO;2-1. PMID 5549492.
  40. 1 2 3 4 5 6 "Hydroxyprogesterone".
  41. ↑ Donna Shoupe; Daniel R. Mishell (1987). "Therapeutic Regimens". In Daniel R. Mishell (ed.). Menopause: Physiology and Pharmacology. Year Book Medical. pp. 335–351. ISBN 9780815159148.
  42. ↑ Agostini, Riccardo; Casini, Maria Luisa; Costabile, Loredana; Paragona, Mizar; Marzano, Francesca; Unfer, Vittorio (2005). "Efficacy and safety of 17α-hydroxyprogesterone caproate in hormone replacement therapy". Gynecological Endocrinology. 21 (5): 265–267. doi:10.1080/09513590500368650. ISSN 0951-3590. PMID 16373245. S2CID 71508663.
  43. 1 2 3 Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 266–. ISBN 978-1-4612-5476-8.
  44. 1 2 Ablin RJ, Mason MD (5 September 2007). Metastasis of Prostate Cancer. Springer Science & Business Media. pp. 286–. ISBN 978-1-4020-5847-9.
  45. ↑ Smith PH (29 June 2013). Cancer of the Prostate and Kidney. Springer Science & Business Media. pp. 309, 339. ISBN 978-1-4684-4349-3.
  46. 1 2 Hafez ES, Spring-Mills E (6 December 2012). Prostatic Carcinoma: Biology and Diagnosis. Springer Science & Business Media. pp. 128–. ISBN 978-94-009-8887-3.
  47. 1 2 3 Castro JE (9 March 2013). The Treatment of Prostatic Hypertrophy and Neoplasia. Springer Science & Business Media. pp. 39, 132. ISBN 978-94-015-7190-6. Geller has also demonstrated significant decreases in plasma or urine testosterone glucuronide levels following the administration of three other anti-androgens. These include Delalutin [hydroxyprogesterone caproate], chlormadinone acetate, and PH-218. It would appear that decreased androgen production is a property shared by all anti-androgens to date.
  48. ↑ Aronson JK (21 February 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. pp. 289–. ISBN 978-0-08-093292-7.
  49. ↑ Israel GE, Tarver DE, Shaffer JD (1 March 2001). Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts. Temple University Press. pp. 58–. ISBN 978-1-56639-852-7.
  50. ↑ Ekins R, King D (23 October 2006). The Transgender Phenomenon. SAGE Publications. pp. 48–. ISBN 978-1-84787-726-0.
  51. ↑ Adler RK, Hirsch S, Mordaunt M (1 May 2012). Voice and Communication Therapy for The Transgender/Transsexual Client: A Comprehensive Clinical Guide. Plural Publishing. pp. 486–. ISBN 978-1-59756-631-5.
  52. ↑ Masumori N (May 2012). "Status of sex reassignment surgery for gender identity disorder in Japan". International Journal of Urology. 19 (5): 402–14. doi:10.1111/j.1442-2042.2012.02975.x. PMID 22372595. S2CID 38888396.
  53. ↑ Chekir C, Emi Y, Arai F, Kikuchi Y, Sasaki A, Matsuda M, Shimizu K, Tabuchi K, Kamada Y, Hiramatsu Y, Nakatsuka M (June 2012). "Altered arterial stiffness in male-to-female transsexuals undergoing hormonal treatment". The Journal of Obstetrics and Gynaecology Research. 38 (6): 932–40. doi:10.1111/j.1447-0756.2011.01815.x. PMID 22487218. S2CID 39877004.
  54. 1 2 Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 757–759, 2168. ISBN 978-0-7817-1750-2.
  55. ↑ Nema S, Ludwig JD (19 April 2016). Pharmaceutical Dosage Forms - Parenteral Medications, Third Edition: Volume 1: Formulation and Packaging. CRC Press. pp. 161–. ISBN 978-1-4200-8644-7.
  56. 1 2 Muller NF, Dessing RP (19 June 1998). European Drug Index: European Drug Registrations (Fourth ed.). CRC Press. pp. 561–. ISBN 978-3-7692-2114-5.
  57. 1 2 Garza-Flores J (April 1994). "Pharmacokinetics of once-a-month injectable contraceptives". Contraception. 49 (4): 347–59. doi:10.1016/0010-7824(94)90032-9. PMID 8013219.
  58. 1 2 3 4 5 Sang GW (April 1994). "Pharmacodynamic effects of once-a-month combined injectable contraceptives". Contraception. 49 (4): 361–85. doi:10.1016/0010-7824(94)90033-7. PMID 8013220.
  59. 1 2 Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S (2014). "Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control" (PDF). World J Pharm Pharm Sci. 3 (10): 364–392. ISSN 2278-4357. Archived from the original (PDF) on 2017-08-10. Retrieved 2018-09-15.
  60. 1 2 3 Leidenberger FA (17 April 2013). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. pp. 533–. ISBN 978-3-662-08110-5.
  61. 1 2 3 4 5 Knörr K, Beller FK, Lauritzen C (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 214, 255. ISBN 978-3-662-00942-0.
  62. 1 2 3 Kahr H (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 22–. ISBN 978-3-7091-5694-0.
  63. 1 2 3 Kern W, Auterhoff H, Neuwald F, Schmid W (9 March 2013). Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte und Medizinalbeamte. Springer-Verlag. pp. 1163–. ISBN 978-3-642-49759-9.
  64. 1 2 3 4 5 6 7 8 Ufer, Joachim (1968). "Die therapeutische Anwendung der Gestagene beim Menschen" [Therapeutic Use of Progestogens in Humans]. Die Gestagene [Progestogens]. Springer-Verlag. pp. 1026–1124. doi:10.1007/978-3-642-99941-3_7. ISBN 978-3-642-99941-3. Depotinjektionen [...] 2. Einmalige Injektion von 125mg oder 250mg 17α-Hydroxyprogesteroncapronat als Depotgestagen und 10 mg Oestradiolbenzoat in öliger Lösung (Primosiston) [47, 81, 110, 563, 523, 571, 718, 721, 732, 733, 864, 872, 933, 973, 400].
  65. ↑ "Archived copy". Archived from the original on 2019-04-07. Retrieved 2019-06-01.{{cite web}}: CS1 maint: archived copy as title (link)
  66. ↑ Noguchi M, Tajiri K, Taniya T, Kumaki T, Ashikari A, Miyazaki I (1990). "Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7)". Oncology. 47 (1): 19–24. doi:10.1159/000226779. PMID 2137212. After the transplantation, each mouse received an intramuscular injection of 0.1 ml EP Hormone Depot consisting of 1 mg/ml 17-β-estradiol dipropionate and 50 mg/ml hydroxyprogesterone caproate every week.
  67. ↑ Tyler ET, Olson HJ (April 1959). "Fertility promoting and inhibiting effects of new steroid hormonal substances". J Am Med Assoc. 169 (16): 1843–54. doi:10.1001/jama.1959.03000330015003. PMID 13640942.
  68. 1 2 Hall NR (June 2011). "What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?". Obstetrics and Gynecology Clinics of North America. 38 (2): 235–46, ix–x. doi:10.1016/j.ogc.2011.02.014. PMID 21575799.
  69. 1 2 Varga A, Henriksen E. Clinical and Histopathologic Evaluation of the Effect of 17-alpha-Hydroxyprogesterone-17-n-caproate on Endometrial Carcinoma. Obstetrics & Gynecology. December 1961. Volume 18. Issue 6. pp. 658-672.
  70. ↑ Knörr K, Beller FK, Lauritzen C (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 214–. ISBN 978-3-662-00942-0.
  71. ↑ Knörr K, Knörr-Gärtner H, Beller FK, Lauritzen C (8 March 2013). Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion. Springer-Verlag. pp. 583–. ISBN 978-3-642-95583-9.
  72. ↑ A. Labhart (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 554–. ISBN 978-3-642-96158-8.
  73. ↑ Horský J, Presl J (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". In Horsky J, Presl K (eds.). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN 978-94-009-8195-9.
  74. ↑ Joachim Ufer (1969). The Principles and Practice of Hormone Therapy in Gynaecology and Obstetrics. de Gruyter. p. 49. 17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce secretory changes in primed endometrium is about 250 mg. per menstrual cycle.
  75. ↑ Willibald Pschyrembel (1968). Praktische Gynäkologie: für Studierende und Ärzte. Walter de Gruyter. pp. 598, 601. ISBN 978-3-11-150424-7.
  76. ↑ Ferin J (September 1972). "Effects, Duration of Action and Metabolism in Man". In Tausk M (ed.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Vol. II. Pergamon Press. pp. 13–24. ISBN 978-0080168128. OCLC 278011135.
  77. ↑ Henzl MR, Edwards JA (10 November 1999). "Pharmacology of Progestins: 17α-Hydroxyprogesterone Derivatives and Progestins of the First and Second Generation". In Sitruk-Ware R, Mishell DR (eds.). Progestins and Antiprogestins in Clinical Practice. Taylor & Francis. pp. 101–132. ISBN 978-0-8247-8291-7.
  78. ↑ Janet Brotherton (1976). Sex Hormone Pharmacology. Academic Press. p. 114. ISBN 978-0-12-137250-7.
  79. ↑ Sang GW (April 1994). "Pharmacodynamic effects of once-a-month combined injectable contraceptives". Contraception. 49 (4): 361–85. doi:10.1016/0010-7824(94)90033-7. PMID 8013220.
  80. ↑ Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.
  81. ↑ Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S (2014). "Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control" (PDF). World J Pharm Pharm Sci. 3 (10): 364–392. ISSN 2278-4357. Archived from the original (PDF) on 2017-08-10. Retrieved 2016-08-24.
  82. ↑ Goebelsmann U (1986). "Pharmacokinetics of Contraceptive Steroids in Humans". In Gregoire AT, Blye RP (eds.). Contraceptive Steroids: Pharmacology and Safety. Springer Science & Business Media. pp. 67–111. doi:10.1007/978-1-4613-2241-2_4. ISBN 978-1-4613-2241-2.
  83. ↑ Becker H, Düsterberg B, Klosterhalfen H (1980). "[Bioavailability of cyproterone acetate after oral and intramuscular application in men (author's transl)]" [Bioavailability of Cyproterone Acetate after Oral and Intramuscular Application in Men]. Urologia Internationalis. 35 (6): 381–5. doi:10.1159/000280353. PMID 6452729.
  84. ↑ Moltz L, Haase F, Schwartz U, Hammerstein J (May 1983). "[Treatment of virilized women with intramuscular administration of cyproterone acetate]" [Efficacy of Intra muscularly Applied Cyproterone Acetate in Hyperandrogenism]. Geburtshilfe Und Frauenheilkunde. 43 (5): 281–7. doi:10.1055/s-2008-1036893. PMID 6223851.
  85. ↑ Wright JC, Burgess DJ (29 January 2012). Long Acting Injections and Implants. Springer Science & Business Media. pp. 114–. ISBN 978-1-4614-0554-2.
  86. ↑ Chu YH, Li Q, Zhao ZF (April 1986). "Pharmacokinetics of megestrol acetate in women receiving IM injection of estradiol-megestrol long-acting injectable contraceptive". The Chinese Journal of Clinical Pharmacology. The results showed that after injection the concentration of plasma MA increased rapidly. The meantime of peak plasma MA level was 3rd day, there was a linear relationship between log of plasma MA concentration and time (day) after administration in all subjects, elimination phase half-life t1/2β = 14.35 ± 9.1 days.
  87. ↑ Runnebaum BC, Rabe T, Kiesel L (6 December 2012). Female Contraception: Update and Trends. Springer Science & Business Media. pp. 429–. ISBN 978-3-642-73790-9.
  88. ↑ Artini PG, Genazzani AR, Petraglia F (11 December 2001). Advances in Gynecological Endocrinology. CRC Press. pp. 105–. ISBN 978-1-84214-071-0.
  89. ↑ King TL, Brucker MC, Kriebs JM, Fahey JO (21 October 2013). Varney's Midwifery. Jones & Bartlett Publishers. pp. 495–. ISBN 978-1-284-02542-2.
  90. 1 2 Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  91. 1 2 Knörr K, Knörr-Gärtner H, Beller FK, Lauritzen C (8 March 2013). Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion. Springer-Verlag. pp. 583–. ISBN 978-3-642-95583-9.
  92. ↑ Lauritzen C (September 1990). "Clinical use of oestrogens and progestogens". Maturitas. 12 (3): 199–214. doi:10.1016/0378-5122(90)90004-P. PMID 2215269.
  93. 1 2 Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.
  94. 1 2 Siegel I (June 1963). "Conception control by long-acting progestogens: preliminary report". Obstetrics and Gynecology. 21: 666–8. doi:10.1097/00006250-196306000-00003 (inactive 31 October 2021). PMID 13992789.{{cite journal}}: CS1 maint: DOI inactive as of October 2021 (link)
  95. ↑ Kistner RW (December 1960). "The use of progestational agents in obstetrics and gynecology". Clinical Obstetrics and Gynecology. 3 (4): 1047–67. doi:10.1097/00003081-196003040-00019. PMID 13756432. 50 mg of [medroxyprogesterone acetate], intramuscularly, is equivalent to 250 mg [hydroxyprogesterone caproate]
  96. ↑ "Depo_Provera" (PDF). FDA. 2016. Retrieved 31 March 2018.
  97. 1 2 3 4 5 6 7 8 Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN (December 2007). "Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins". American Journal of Obstetrics and Gynecology. 197 (6): 599.e1–7. doi:10.1016/j.ajog.2007.05.024. PMC 2278032. PMID 18060946.
  98. ↑ Yang D, Zhu RL (April 1994). "[Changes in reproductive hormones levels in the treatment of endometrial precancerous lesion with hydroxyprogesterone caproate]". Zhonghua Fu Chan Ke Za Zhi (in Chinese). 29 (4): 205–6, 251. PMID 8082440. In this paper, 14 cases of precancerous lesion of endometrium were treated with hydroxyprogesterone caproate and a series of hormone determination was analysed before and after treatment. Results showed that LH and LH/FSH were dramatically decreased. (LH P < 0.05, LH/FSH P < 0.01).
  99. ↑ Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 266–. ISBN 978-1-4612-5476-8. Since the initial report by Geller and associates28 on the use of hydroxyprogesterone caproate in the treatment of BPH, a variety of progestins have been studied in the medical management of this disease: hydroxyprogesterone caproate, chlormadinone acetate,27 and medrogestone (6-methyl-6-dehydro-17-methylprogesterone).50 These drugs should have a beneficial effect in BPH as they inhibit testicular function by suppressing serum LH and have no intrinsic estrogenic or androgenic activity.
  100. ↑ Meiraz D, Margolin Y, Lev-Ran A, Lazebnik J (February 1977). "Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate: placebo-controlled study". Urology. 9 (2): 144–8. doi:10.1016/0090-4295(77)90184-4. PMID 65818.
  101. ↑ Geller J, Fruchtman B, Newman H, Roberts T, Silva R (February 1967). "Effect of progestational agents on carcinoma of the prostate". Cancer Chemother Rep. 51 (1): 41–6. PMID 6039663.
  102. ↑ Karlstedt K (April 1971). "Progesterone treatment for local recurrence and metastases in carcinoma corporis uteri". Acta Radiologica. 10 (2): 187–92. doi:10.3109/02841867109129755. PMID 5556820. The preparations used were Proluton Depot (17a-hydroxy-progesterone caproate) and in 3 patients SH 5132 (17a-hydroxy-19-norprogesterone caproate); 100 mg of the latter corresponds to 1000 mg of Proluton Depot.
  103. 1 2 Moe N (1972). "Short-term progestogen treatment of endometrial carcinoma. Histological, histochemical and hormonal studies". Acta Obstetricia et Gynecologica Scandinavica. 51 (1): 55–62. doi:10.3109/00016347209154968. PMID 4261828. S2CID 7181971.
  104. 1 2 3 Sander S, Nissen-Meyer R, Aakvaag A (1978). "On gestagen treatment of advanced prostatic carcinoma". Scandinavian Journal of Urology and Nephrology. 12 (2): 119–21. doi:10.3109/00365597809179977. PMID 694436.
  105. 1 2 Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, Kahn F, Sood R, Joplin GF (November 1979). "Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men". Clinical Endocrinology. 11 (5): 497–504. doi:10.1111/j.1365-2265.1979.tb03102.x. PMID 519881. S2CID 5836155. Another synthetic gestogen, 17-hydroxy-19-norprogesterone caproate (Depostat-Schering), 400 mg by i.m. weekly injections suppressed T levels to 25% of pretreatment values (Sander er al., 1978).
  106. ↑ Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (25 August 2011). Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. pp. 2938–. ISBN 978-1-4160-6911-9.
  107. ↑ Knuth UA, Hano R, Nieschlag E (November 1984). "Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men". The Journal of Clinical Endocrinology and Metabolism. 59 (5): 963–9. doi:10.1210/jcem-59-5-963. PMID 6237116.
  108. ↑ Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (June 1980). "Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial". British Journal of Urology. 52 (3): 208–15. doi:10.1111/j.1464-410x.1980.tb02961.x. PMID 7000222.
  109. ↑ Sherman AI, Woolf RB (February 1959). "An endocrine basis for endometrial carcinoma". American Journal of Obstetrics and Gynecology. 77 (2): 233–42. doi:10.1016/0002-9378(59)90223-6. PMID 13617315.
  110. ↑ Geer EB (1 December 2016). The Hypothalamic-Pituitary-Adrenal Axis in Health and Disease: Cushing's Syndrome and Beyond. Springer. pp. 28–. ISBN 978-3-319-45950-9.
  111. ↑ Aschenbrenner DS, Venable SJ (2009). Drug Therapy in Nursing. Lippincott Williams & Wilkins. pp. 674–. ISBN 978-0-7817-6587-9.
  112. ↑ Gerber AN, Masuno K, Diamond MI (March 2009). "Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening". Proceedings of the National Academy of Sciences of the United States of America. 106 (12): 4929–34. Bibcode:2009PNAS..106.4929G. doi:10.1073/pnas.0812308106. PMC 2660744. PMID 19255438.
  113. 1 2 Bardin CW, Brown T, Isomaa VV, Jänne OA (1983). "Progestins can mimic, inhibit and potentiate the actions of androgens". Pharmacology & Therapeutics. 23 (3): 443–59. doi:10.1016/0163-7258(83)90023-2. PMID 6371845.
  114. 1 2 3 Crowley, Lawrence G.; Macdonald, Ian (1965). "Delalutin and estrogens for the treatment of advanced mammary carcinoma in the postmenopausal woman". Cancer. 18 (4): 436–446. doi:10.1002/1097-0142(196504)18:4<436::AID-CNCR2820180407>3.0.CO;2-D. ISSN 0008-543X. PMID 14278040.
  115. 1 2 Anderson L, Martin W, Higgins C, Nelson SM, Norman JE (November 2009). "The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy". Reproductive Sciences. 16 (11): 1052–61. doi:10.1177/1933719109340926. PMID 19602723. S2CID 6856556.
  116. ↑ Cupps PT (20 February 1991). Reproduction in Domestic Animals. Elsevier. pp. 101–. ISBN 978-0-08-057109-6.
  117. 1 2 Gellersen B, Fernandes MS, Brosens JJ (2009). "Non-genomic progesterone actions in female reproduction". Human Reproduction Update. 15 (1): 119–38. doi:10.1093/humupd/dmn044. PMID 18936037.
  118. 1 2 Schumacher M, Mattern C, Ghoumari A, Oudinet JP, Liere P, Labombarda F, Sitruk-Ware R, De Nicola AF, Guennoun R (February 2014). "Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors". Progress in Neurobiology. 113: 6–39. doi:10.1016/j.pneurobio.2013.09.004. PMID 24172649. S2CID 207407117.
  119. ↑ Mellor DJ, Diesch TJ, Gunn AJ, Bennet L (November 2005). "The importance of 'awareness' for understanding fetal pain". Brain Research. Brain Research Reviews. 49 (3): 455–71. doi:10.1016/j.brainresrev.2005.01.006. PMID 16269314. S2CID 9833426.
  120. ↑ Lagercrantz H, Changeux JP (March 2009). "The emergence of human consciousness: from fetal to neonatal life". Pediatric Research. 65 (3): 255–60. doi:10.1203/PDR.0b013e3181973b0d. PMID 19092726. S2CID 39391626. [...] the fetus is sedated by the low oxygen tension of the fetal blood and the neurosteroid anesthetics pregnanolone and the sleep-inducing prostaglandin D2 provided by the placenta (36).
  121. 1 2 3 Caritis SN, Sharma S, Venkataramanan R, Hankins GD, Miodovnik M, Hebert MF, Umans JG, Benedetti T, Mattison D, Zajicek A, Fischer D, Jackson A (November 2012). "Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation". American Journal of Obstetrics and Gynecology. 207 (5): 398.e1–8. doi:10.1016/j.ajog.2012.08.015. PMC 3586341. PMID 22967833.
  122. 1 2 Caritis SN, Sharma S, Venkataramanan R, Rouse DJ, Peaceman AM, Sciscione A, Spong CY, Varner MW, Malone FD, Iams JD, Mercer BM, Thorp JM, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M (July 2011). "Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation". American Journal of Obstetrics and Gynecology. 205 (1): 40.e1–8. doi:10.1016/j.ajog.2011.03.028. PMC 3165062. PMID 21620357.
  123. ↑ Ferin J (September 1972). "Orally Active Progestational Compounds. Human Studies: Effects on the Utero-Vaginal Tract". In M. Tausk (ed.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Vol. II. Pergamon Press. pp. 245–273. ISBN 978-0080168128. OCLC 278011135.
  124. ↑ Boschann HW (July 1958). "Observations of the role of progestational agents in human gynecologic disorders and pregnancy complications". Ann. N. Y. Acad. Sci. 71 (5): 727–52. Bibcode:1958NYASA..71..727B. doi:10.1111/j.1749-6632.1958.tb46803.x. PMID 13583829.
  125. ↑ Pots P (April 1957). "Die perorale wirksamkeit synthetischer gestagene" [The effectiveness of peroral synthetic gestagens]. Zentralbl Gynakol (in German). 79 (14): 529–39. PMID 13443471.
  126. 1 2 3 "Hydroxyprogesterone caproate oral - Lipocine - AdisInsight".
  127. 1 2 DelConte A, Chidambaram N, Nachaegari S, Patel M, Venkateshwaran S (January 2015). "770: Pharmacokinetics and tolerability of oral 17-hydroxyprogesterone caproate (HPC) relative to intramuscular (IM) HPC". American Journal of Obstetrics & Gynecology. 212 (1): S374. doi:10.1016/j.ajog.2014.10.976.
  128. ↑ Boggess KA, Baker JB, Murtha AP, Peaceman AM, Shah DM, Siegfried SL, Birch R (April 2018). "Pharmacokinetics of Hydroxyprogesterone Caproate and its Primary Metabolites during Pregnancy". AJP Reports. 8 (2): e106–e112. doi:10.1055/s-0038-1639331. PMC 5951785. PMID 29765789.
  129. 1 2 https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021945s000lbl.pdf
  130. 1 2 Ferin J (September 1972). "Effects, Duration of Action and Metabolism in Man". In Tausk M (ed.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Vol. II. Pergamon Press. pp. 13–24. ISBN 978-0080168128. OCLC 278011135.
  131. 1 2 Baker KC (November 1958). "Treatment of persistent acne in women with 17 alpha hydroxyprogesterone caproate (delalutin); a preliminary report". The Journal of Investigative Dermatology. 31 (5): 247–50. doi:10.1038/jid.1958.114. PMID 13598928.
  132. ↑ Santhosh, C. R. (2006). Pharmacokinetics of 17α-Hydroxy Progesterone Caproate in Cattle, Buffalo, Sheep and Goat (Doctoral dissertation, Karnataka Veterinary, Animal and Fisheries Sciences University, Bidar). http://krishikosh.egranth.ac.in/handle/1/68575
  133. 1 2 3 4 5 6 7 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 664–. ISBN 978-1-4757-2085-3.
  134. ↑ Engel J, Kleemann A, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 677–679. ISBN 978-3-13-179275-4.
  135. ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 1865–1866. ISBN 978-0-8155-1856-3.
  136. ↑ Junkmann, Karl; Langecker, Hedwig; Damrosch, Leonore (1968). "Chemie der Gestagene" [Chemistry of Progestogens]. Die Gestagene [Progestogens]. Springer-Verlag. pp. 1–44. doi:10.1007/978-3-642-99941-3_1. ISBN 978-3-642-99941-3. 3. Hydroxyprogesteron-caproat. C27H4004, Mol.-Gew.: 428,62; chemische Bezeichnung Δ4-Pregnen-17α-ol-3,20-dion-17α-capronat, Trivialnamen: Hydroxyprogesteroncapronat, 17α-Hydroxyprogesteron-17α-capronat. Synthese: [88]. Darstellung: [88]. Eigenschaften: weißes kristallines Pulver (aus Isopropyläther) oder Methanol, F.: 119-122⁰, [α]D: +60⁰ (Chlf.) UV-Absorption: λmax.: 240 mμ, ε = 17000. Dipolmoment: [μ = 2,21 (Benzol). Leicht löslich in Äthanol, Äther, Essigester, Benzol, Chloroform, löslich in: Petroläther, unlöslich in Wasser. Bei 20⁰ lösen 100 ml Sesamöl ca. 4,0 g, Ricinusöl ca. 2,5 g, Ricinusöl: Benzylbenzoat (4: 6) ca. 26,5 g, Benzylbenzoat ca. 36,0 g. [...] Abb. 3. IR-Spektrum [126] und Formel des Hydroxyprogesteron-caproat.
  137. ↑ Junkmann K (1954). "Über protrahiert wirksame Gestagene". Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie. 223 (3). doi:10.1007/BF00246995. S2CID 33591186.
  138. ↑ Wied GL, Davis ME (July 1958). "Comparative activity of progestational agents on the human endometrium and vaginal epithelium of surgical castrates". Annals of the New York Academy of Sciences. 71 (5): 599–616. Bibcode:1958NYASA..71..599W. doi:10.1111/j.1749-6632.1958.tb46791.x. PMID 13583817. In the group of new parenteral progestational agents, three substances developed by Karl Junkmann1,2 are the most outstanding and interesting: 17a-hydroxyprogesterone caproate and 17a-hydroxyprogesterone acetate, introduced in 1953, and the most potent of all new parenteral progestational agents, 17-ethynyl-19-nortestosterone enanthate, introduced in 1956.
  139. ↑ ACRH. U.S. Dept. of Energy. 1960. p. 71. [The] minimal activity [of 17(a)-hydroxyprogesterone] is magnified to an unexpected degree by the esterification of this steroid with caproic acid to produce 17(a)-hydroxyprogesterone-17-n-caproate, first reported by Karl Junkmann in 1954.6,7
  140. ↑ Dorfman RI (1966). Methods in Hormone Research. Academic Press. p. 86. Junkmann (1954) reported that the acetate, butyrate, and caproate forms had both increased and prolonged activity, [...]
  141. ↑ Applezweig N (1962). Steroid Drugs. Blakiston Division, McGraw-Hill. pp. 101–102. Junkmann of Schering, AG., however, was able to show that long chain esters of 17a-hydroxyprogesterones such as the 17a-caproate produced powerful long-acting progestational effect. This compound is marketed in the United States as Delalutin by Squibb, and has been heavily used for the treatment of habitual abortion.
  142. ↑ New and Nonofficial Drugs. Lippincott. 1958. p. 662. Supplied by.—E. R. Squibb & Sons (Delalutin). Year of introduction: 1956.
  143. ↑ Tausk M (1975). Pharmacology of hormones. Thieme. p. 105. ISBN 978-3-13-518901-7. Progesterone itself is now almost never used for the management of any imminent threat to pregnancy. For oral therapy, it is in any event unsuitable and for injections, it has now been replaced by the long-acting esters of 17α-hydroxyprogesterone. The caproate (Proluton, Delalutin), a long-acting ester, is available in [...] Progesterone is rarely used therapeutically. It has largely been superseded by a long-acting ester of 17α-hydroxyprogesterone, for parenteral therapy.
  144. ↑ FDA press release regarding Makena approval
  145. ↑ O'Brien JM (September 2013). "Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens". Ultrasound in Obstetrics & Gynecology. 42 (3): 247–53. doi:10.1002/uog.12456. PMID 23495199. S2CID 45600479.
  146. 1 2 3 Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. pp. 2110–2111. ISBN 978-0-85369-840-1.
  147. ↑ "Price of preterm birth medicine cut". Boston.com. Associated Press. April 2, 2011. Retrieved April 2, 2011.
  148. ↑ Antibiotic Medicine and Clinical Therapy. 1959. p. 249.
  149. ↑ Mokhtar K. Toppozada (1983). "Monthly Injectable Contraceptives". In Alfredo Goldsmith; Mokhtar Toppozada (eds.). Long-Acting Contraception. pp. 93–103. OCLC 35018604.
  150. ↑ Toppozada M (June 1977). "The clinical use of monthly injectable contraceptive preparations". Obstetrical & Gynecological Survey. 32 (6): 335–47. doi:10.1097/00006254-197706000-00001. PMID 865726.
  151. ↑ Dao, Thomas L. (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli; David G. Johns (eds.). Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8.
  152. ↑ Crowley, Lawrence G.; Macdonald, Ian (1962). "Clinical trial of Delalutin in the treatment of advanced mammary carcinoma in postmenopausal women". Cancer. 15 (6): 1218–1220. doi:10.1002/1097-0142(196211/12)15:6<1218::AID-CNCR2820150619>3.0.CO;2-Y. ISSN 0008-543X. PMID 14024037.
  153. ↑ Geller J, Volk H, Lewin M (October 1961). "Objective remission of metastatic breast carcinoma in a male who received 17-alpha hydroxy progesterone caproate (Delalutin)". Cancer Chemotherapy Reports. 14: 77–81. ISSN 0069-0112. PMID 13897631.
  154. ↑ Crowley, L.G.; MacDonald, J. (1966). "Delalutin und Östrogene als Behandlung des vorgeschrittenen Mammakarzinoms bei Frauen nach der Menopause" [Delalutin and estrogens as a treatment for advanced breast cancer in postmenopausal women]. Gynäkologisch-geburtshilfliche Rundschau. 3 (4): 271–272. doi:10.1159/000266855. ISSN 1018-8843.
  155. ↑ Firusian N, Schietzel M (September 1976). "Zur additiven Therapie des metastasierenden Mamma-Karzinoms unter Berücksichtigung des Postmenopausalaltes (Ergebnisse einer randomisierten Studie)" [Additive treatment of metastasizing breast cancer with special reference to postmenopausal age (results of a randomized study)]. Strahlentherapie (in German). 152 (3): 235–47. ISSN 0039-2073. PMID 968923.

Further reading

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.